Skip to content
Search

Latest Stories

Submit Guest Post

Devi Shetty’s AI powered mobile- first hospital platform aims to transform NHS care

Dr Devi Shetty's Narayana Health performs 36 heart surgeries daily while entire NHS does 65 now brings mobile-first platform to Britain

Devi Shetty AI hospital platform

The Wellsoon service targets ordinary workers, with 80 per cent having never used private healthcare previously.

Getty Images

Highlights

  • Billionaire cardiovascular surgeon's hospitals perform heart surgeries at $1,500 compared to $70,000 in America through economies of scale.
  • AI-powered mobile platform developed over 20 years by 250 engineers instantly alerts doctors to critical test results, reducing medical errors.
  • Practice Plus Group acquisition gives NHS-trained doctor gateway to treat more British patients while cutting healthcare costs.

An Indian-origin billionaire surgeon who cared for Mother Teresa and trained in the NHS has developed an AI-powered hospital system he believes can solve Britain's healthcare crisis, revealed his plans in an interview with The Telegraph.

Dr Devi Shetty, 72, founder of India's largest hospital network Narayana Health, recently acquired Practice Plus Group hospitals in the UK and is preparing to roll out a mobile-first technology platform that has revolutionised healthcare delivery across India and Kenya.


The cardiovascular surgeon, who trained at Leeds's Killingbeck Hospital, Royal Brompton and Guy's Hospital in London during the 1980s, told The Telegraph his Bangalore hospital schedules 36 heart surgeries daily while the entire NHS performs around 65 to 70 across all centres combined.

"I am convinced the NHS is one of the few systems in the world that can truly transform itself," Dr Shetty said.

"The pieces are there, the expertise, the workforce, the trust, it's a single payer on a national scale. It just needs to be put together."

Affordable healthcare

His organisation has invested over $100 million developing a real-time AI system operated by 250 software engineers.

The platform, which resembles WhatsApp in design, instantly delivers test results and imaging reports to doctors' mobile phones rather than desktop terminals checked only periodically throughout the day.

"Medical error is the third leading cause of death in the US," Dr Shetty explained, noting deadly lab results might return at 6pm but go unseen until morning.

His integrated AI reviews more than 70 data points per patient and suggests required interventions. "It is like a brilliant doctor standing behind every bed," he said.

The surgeon's approach centres on economies of scale. Heart bypass surgery costing $70,000 in America costs around $1,500 at his hospitals using identical equipment. "If a solution isn't affordable, it is not a solution," he stated.

Dr Shetty, who cared for Nobel Peace Prize winner Mother Teresa for five years until her death, said she "completely changed my attitude towards my profession, and society."

His teams are now preparing the system for GDPR compliance ahead of an imminent UK rollout through Practice Plus Group, which already treats high volumes of NHS patients.

The Wellsoon service targets ordinary workers, with 80 per cent having never used private healthcare previously.

"I don't mind if nobody remembers me after I die, I only want to see a world where everyone has access to healthcare," Dr Shetty said.

Add EasternEye As Your Trusted Source
preferred source on google news

More For You

cancer treatment

The NHS availability announced in September 2026 applies to eligible patients in England. The treatment has already been available in Scotland for more than two years.

What is Enhertu and how could the new NHS breast cancer treatment help patients?

Highlights:
  • Enhertu is a targeted treatment for certain HER2-low breast cancers.
  • It is available for around 1,000 women in England.
  • The drug can extend survival compared with chemotherapy.
  • NICE initially rejected widespread NHS use in 2024.
  • The decision was reversed after a commercial agreement was reached.

Breast cancer treatment continues to evolve as researchers develop therapies aimed at specific characteristics of cancer cells. One such treatment is Enhertu, which has now become available on the NHS in England for people with a particular type of advanced breast cancer.

The treatment is intended for patients with HER2-low breast cancer that cannot be removed through surgery or has spread to other parts of the body. This is known as metastatic breast cancer. According to the latest announcement, around 1,000 women in England will be eligible for the treatment.

Keep ReadingShow less